ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Xilio Therapeutics Inc

Xilio Therapeutics Inc (XLO)

1.02
0.0201
(2.01%)
Closed July 14 4:00PM
1.04
0.02
(1.96%)
After Hours: 5:03PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.04
Bid
0.70
Ask
2.19
Volume
80,209
0.9803 Day's Range 1.03
0.49 52 Week Range 2.94
Market Cap
Previous Close
0.9999
Open
0.9937
Last Trade
15
@
1.04
Last Trade Time
Financial Volume
$ 80,405
VWAP
1.0024
Average Volume (3m)
309,207
Shares Outstanding
36,912,373
Dividend Yield
-
PE Ratio
-0.49
Earnings Per Share (EPS)
-2.07
Revenue
-
Net Profit
-76.4M

About Xilio Therapeutics Inc

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immuno... Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Xilio Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XLO. The last closing price for Xilio Therapeutics was $1. Over the last year, Xilio Therapeutics shares have traded in a share price range of $ 0.49 to $ 2.94.

Xilio Therapeutics currently has 36,912,373 shares outstanding. The market capitalization of Xilio Therapeutics is $36.91 million. Xilio Therapeutics has a price to earnings ratio (PE ratio) of -0.49.

XLO Latest News

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.1820.93023255810.861.030.86933620.96512301CS
40.021.960784313731.021.050.8522221328130.92703401CS
12-0.21-16.81.251.320.83663092071.05211418CS
260.223.80952380950.841.930.50017520901.17789629CS
52-1.56-602.62.940.494078481.14889065CS
156-13.96-93.06666666671527.950.491960802.53467841CS
260-13.96-93.06666666671527.950.491960802.53467841CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VEVVicinity Motor Corporation
$ 0.7131
(122.15%)
116.26M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
IVPInspire Veterinary Partners Inc
$ 10.52
(88.19%)
41.79M
TOYOTOYO Company Ltd
$ 2.699
(74.13%)
56.65M
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
(51.33%)
7.4M
SISIShineco Inc
$ 0.8446
(-60.16%)
6.71M
MCACMonterey Capital Acquisition Corporation
$ 3.54
(-49.50%)
364.7k
MCACUMonterey Capital Acquisition Corporation
$ 7.64
(-28.40%)
2.61k
GENEGenetic Technologies Ltd
$ 0.80
(-27.93%)
780.46k
KZIAKazia Therapeutics Ltd
$ 0.8975
(-27.62%)
25.62M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.237
(-1.54%)
286.13M
NVDANVIDIA Corporation
$ 129.24
(1.44%)
251.69M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
(21.92%)
192.82M
LCIDLucid Group Inc
$ 4.25
(25.00%)
167.79M

XLO Discussion

View Posts
PonkenPlonken PonkenPlonken 1 month ago
XLO -- unique masking approach and great results. Hot field $JANX. Gilead certainly thinks so - buys real equity. Company trades below the upfront payment...

https://schrts.co/tdtYZDEX
πŸ‘οΈ0
Preciouslife1 Preciouslife1 1 month ago
Hi I tried to buy a bunch of shares this morning once at .885 then at .90; never filled though over the ASK PRICE then it took off upwards! MM MANIPULATION MUCH!?!?
πŸ‘οΈ0
Laster Laster 2 months ago
Stock closed the gap. They are in the right biotech area similar to CLRB and CTMX and SNSE.
Only a matter of time before this explodes to $2 or higher.
JMO.
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
XLO under $2
πŸ‘οΈ0
Laster Laster 3 months ago
The chart shows a very nice looking pennant pattern.
Biotechs are not trading well recently.
Any recovery in biotechs then this could get interesting.
Needs to move past $1.50 to confirm breakout.
Enjoy the day.
πŸ‘οΈ0
Laster Laster 3 months ago
I remember when OCEA had similar pennant pattern before it broke out to $7.50.
Crazy times sometimes causes crazy moves.
I like the story here. Seems like a nice biotech to invest into.
JMO.
Enjoy.
πŸ‘οΈ0
Laster Laster 3 months ago
Oops. I blinked. Missed it.
Maybe I will be quicker when it moves back to $1.20.
Unless it pops to $1.50 on no news.
Chart looks interesting. Nice pennant pattern.
Enjoy.
πŸ‘οΈ0
Awl416 Awl416 3 months ago
Don’t blink
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
XLO: Best of luck on this one, Capt. TIm!! (I DID get both of your Post-M iHub 'emails', so I am answering both of them vis-a-vis this single one.) I am still in SHOCK that XLO did NOT soar at least 400% today.

WILD, UNPREDICTABLE, DAY TODAY!!! (And I missed all the glory behind @AVTX, to boot!! BUMMER!!!)
πŸ‘οΈ0
TIMGZ TIMGZ 4 months ago
XLO IS MOVING , HOPEFULLY THE TORTOISE-LIKE CONTINUES*****
IN THE NEXT 3 HOURS AND PR MONDAY SHOULD BE MORE GLORIOUS****WE SHALL SEE***


THAT WAS AN EXCELLENT PR BUT THE PLAN ALL ALONG WAS SNAKE-OIL-LIKE
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
XLO: Worthless piece of SHIT!!!
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
XLO: Oooooooo, Boy!!! (Latest 'Chart', below, looks pretty good!!!)




"I gots my entire weekly ALLOWANCE in this, sucka!!! So you BETTER gets to Planet Jupiter pretty damn QUICK!!!"
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
XLO: Halted.
πŸ‘οΈ0
JPetroInc JPetroInc 4 months ago
nice news on XLO

looks a lot like iBio news

good fortunes to all XLO shareholders …

EOM
💩 1 🤡 1
Awl416 Awl416 4 months ago
Watch out for these dirty algo’s
πŸ‘οΈ0
Awl416 Awl416 4 months ago
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
πŸ‘οΈ0
Awl416 Awl416 4 months ago
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Price target > 36.00 > HC Wainwright & Co. analyst Michael King initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Buy rating and announces Price Target of $36.

Latest Ratings for XLO DateFirmActionFromTo

Jan 2022HC Wainwright & Co.Initiates Coverage OnBuy Nov 2021Raymond JamesInitiates Coverage OnOutperform Nov 2021Cowen & Co.Initiates Coverage OnOutperform

πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
TODAY > Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Rene Russo, Pharm. D., president and chief executive officer, and Marty Huber, M.D., president of research and development and chief medical officer of Xilio Therapeutics, will participate in a virtual fireside chat during the Guggenheim 4 Annual Oncology Day on Thursday, February 10, 2022, at 8:30 a.m. ET.

A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock